NanoMedSyn is a dynamic start-up based in Montpellier, dedicated to revolutionizing the treatment of Lysosomal Storage Disorders. Founded by a team of highly skilled biologists and chemists, NanoMedSyn has developed a groundbreaking technology for delivering drugs to the lysosomal cell compartment, resulting in enhanced therapeutic outcomes. This cutting-edge technology has been extensively validated at the preclinical level and holds tremendous potential across various medical fields, including oncology, immunity, inflammation, and metabolism.

With a team of professional experts boasting years of experience in nanotechnologies, NanoMedSyn continues to innovate and push the boundaries of medical advancements. They have recently recruited new doctors to further strengthen their capabilities, signaling their commitment to making significant strides in the field. By leveraging their patented synthetic derivative, AMFA, which is specifically designed to target the mannose 6-phosphate receptor, NanoMedSyn is well-positioned to revolutionize the treatment landscape for Lysosomal Storage Disorders.

For more information about their groundbreaking work or to get in touch, visit NanoMedSyn's website